loading

Celldex Therapeutics Inc (CLDX) 最新ニュース

pulisher
Mar 27, 2025

Global Cholera Vaccines Market Business Outlook ,Growth - openPR

Mar 27, 2025
pulisher
Mar 23, 2025

Hive Of ActivityCelldex To Report Long-term Results Of Urticaria Drug - RTTNews

Mar 23, 2025
pulisher
Mar 23, 2025

Why Celldex Deserves Your Attention? - RTTNews

Mar 23, 2025
pulisher
Mar 20, 2025

7 Analysts Have This To Say About Celldex Therapeutics - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Celldex a new overweight at Morgan Stanley on urticaria candidate - Seeking Alpha

Mar 20, 2025
pulisher
Mar 20, 2025

This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga

Mar 20, 2025
pulisher
Mar 20, 2025

Morgan Stanley Initiates Coverage of Celldex Therapeutics (CLDX) with Overweight Recommendation - Nasdaq

Mar 20, 2025
pulisher
Mar 20, 2025

MS starts coverage on Celldex, bullish view on company's skin disease treatment - TradingView

Mar 20, 2025
pulisher
Mar 20, 2025

Morgan Stanley Initiates Celldex Therapeutics at Overweight With $46 Price Target -March 20, 2025 at 07:14 am EDT - Marketscreener.com

Mar 20, 2025
pulisher
Mar 18, 2025

Personalized Cancer Vaccines Market | Growth, Innovations & - openPR

Mar 18, 2025
pulisher
Mar 14, 2025

Strategies for Managing Chronic Spontaneous Urticaria - Medscape

Mar 14, 2025
pulisher
Mar 11, 2025

A better buy-in window may exist right now for Celldex Therapeutics Inc (CLDX) - SETE News

Mar 11, 2025
pulisher
Mar 06, 2025

Celldex Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 06, 2025
pulisher
Mar 05, 2025

The Goldman Sachs Group Issues Pessimistic Forecast for Celldex Therapeutics (NASDAQ:CLDX) Stock Price - Armenian Reporter

Mar 05, 2025
pulisher
Mar 04, 2025

Celldex’s CDX-622 shows promise for inflammatory disorders - BioWorld Online

Mar 04, 2025
pulisher
Mar 04, 2025

Celldex Therapeutics to Present at Upcoming Investor Conferences - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

CLDXCelldex Therapeutics Inc Latest Stock News & Market Updates - StockTitan

Mar 04, 2025
pulisher
Mar 04, 2025

H.C. WAINWRIGHT MAINTAINS BUY RATING, $80 TARGET ON CELLDEX STOCK - Investing.com UK

Mar 04, 2025
pulisher
Mar 04, 2025

Celldex Therapeutics (NASDAQ:CLDX) Price Target Lowered to $36.00 at The Goldman Sachs Group - Defense World

Mar 04, 2025
pulisher
Mar 03, 2025

UBS Initiates Coverage of Celldex Therapeutics (CLDX) with Buy Recommendation - MSN

Mar 03, 2025
pulisher
Mar 03, 2025

Celldex Therapeutics Reports Positive Preclinical Data For Inflammation Drug - Nasdaq

Mar 03, 2025
pulisher
Mar 03, 2025

Celldex Therapeutics Presents Positive Preclinical Data from Inflammatory Bispecific Antibody Program CDX-622 at AAAAI 2025 - The Manila Times

Mar 03, 2025
pulisher
Mar 03, 2025

Can Celldex's Dual-Mechanism CDX-622 Transform Inflammatory Disease Treatment? - StockTitan

Mar 03, 2025
pulisher
Mar 03, 2025

Celldex Therapeutics’ (CLDX) Buy Rating Reiterated at HC Wainwright - Defense World

Mar 03, 2025
pulisher
Mar 02, 2025

Celldex announces data from Phase 2 barzolvolimab studies - MSN

Mar 02, 2025
pulisher
Mar 02, 2025

Jasper Therapeutics Presents Clinical and Preclinical Briquilimab Data at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting - The Manila Times

Mar 02, 2025
pulisher
Mar 01, 2025

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients with Chronic Urticaria Demonstrating Improved Disease Control and Quality of Life at AAAAI 2025 - The Manila Times

Mar 01, 2025
pulisher
Mar 01, 2025

Celldex Therapeutics Presents Positive Results from Barzolvolimab Phase 2 Studies in Patients ... - Enid News & Eagle

Mar 01, 2025
pulisher
Mar 01, 2025

Can Celldex's Urticaria Treatment Transform Patient Lives? Phase 2 Data Shows 95% Quality of Life Improvement - StockTitan

Mar 01, 2025
pulisher
Mar 01, 2025

Celldex Therapeutics (NASDAQ:CLDX) Receives Buy Rating from HC Wainwright - MarketBeat

Mar 01, 2025
pulisher
Feb 28, 2025

Celldex Therapeutics (NASDAQ:CLDX) Posts Quarterly Earnings Results, Beats Estimates By $0.02 EPS - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month LowWhat's Next? - MarketBeat

Feb 28, 2025
pulisher
Feb 28, 2025

Forecasting The Future: 6 Analyst Projections For Celldex Therapeutics - Benzinga

Feb 28, 2025
pulisher
Feb 28, 2025

Celldex Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com

Feb 28, 2025
pulisher
Feb 28, 2025

Celldex Reports Fourth Quarter and Year End 2024 Financial Results and Provides Corporate Update - The Manila Times

Feb 28, 2025
pulisher
Feb 28, 2025

Celldex: Q4 Earnings Snapshot - The Washington Post

Feb 28, 2025
pulisher
Feb 27, 2025

Celldex Therapeutics Advances Pipeline Amid Financial Challenges - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex reports Q4 EPS (71c), consensus (71c) - TipRanks

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex Therapeutics (CLDX) Reports Q4 Loss, Lags Revenue Estimates - MSN

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex: Q4 Earnings Snapshot -February 27, 2025 at 04:33 pm EST - Marketscreener.com

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Celldex Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 27, 2025
pulisher
Feb 27, 2025

Can Celldex's $725M War Chest and Promising Clinical Data Deliver Returns for Investors? - StockTitan

Feb 27, 2025
pulisher
Feb 25, 2025

Celldex stock touches 52-week low at $20.86 amid market challenges - Investing.com India

Feb 25, 2025
pulisher
Feb 22, 2025

Celldex Therapeutics Inc (CLDX) Recovers 7.41% From Low: Are We There Yet? - Stocks Register

Feb 22, 2025
pulisher
Feb 22, 2025

Celldex Therapeutics (CLDX) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025
pulisher
Feb 21, 2025

Celldex Therapeutics' SWOT analysis: barzolvolimab drives stock potential - MSN

Feb 21, 2025
pulisher
Feb 21, 2025

Dual Inhibition of Mast Cells and Thymic Stromal Lymphopoietin Using a Novel Bispecific Antibody, CDX-622 - Wiley Online Library

Feb 21, 2025
pulisher
Feb 20, 2025

Chronic Spontaneous Urticaria Market to Register - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire

Feb 20, 2025
pulisher
Feb 20, 2025

Chronic Spontaneous Urticaria Market to Register Incremental Growth During the Study Period (2020–2034) Owing to the Launch of Emerging Therapies | DelveInsight - GlobeNewswire Inc.

Feb 20, 2025
pulisher
Feb 19, 2025

Celldex Therapeutics (CLDX) Expected to Announce Earnings on Monday - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

What is Leerink Partnrs' Forecast for CLDX Q1 Earnings? - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $60.22 Average Price Target from Analysts - MarketBeat

Feb 19, 2025
pulisher
Feb 19, 2025

Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Sold by TSP Capital Management Group LLC - MarketBeat

Feb 19, 2025
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
大文字化:     |  ボリューム (24 時間):